A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft Versus Host Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation.

Trial Profile

A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft Versus Host Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Fludarabine; Melphalan; Rituximab; Sirolimus; Tacrolimus
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 26 May 2017 Status changed from active, no longer recruiting to completed.
    • 06 Aug 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 02 Sep 2011 Planned end date changed from 1 May 2010 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top